1FDA. Safety Warnings Regarding Use of Fentanyl Transdermal(Skin) Patches[EB/OL]. US Food and Drug Administration. [2005-07-15]. http://www.fda.gov/cder/drug/advisory/fentanyl.htm
2Mather LE. Clinical pharmacokinetic studies of fentanyl and its news derivatives[J]. Clin Pharmacokinetics, 1983,8:422-446.
4Zech DF, Groud SU, Lynch J, et al.Transdermal fentanyl and initial dose finding with patient controlled and analgesia in cancer pain: a pilot study with 20 terminally ill cancer patients [J]. Pain, 1992, 50(3):293-301.
5Hwang SS, Nichols KC, Southam M. Transdermal permeation: physiological and physicochemical aspects[M].In:Lehmann KA, Zech D. Transdermal Fentanyl. Berlin Heidelberg: Springer Verlay, 1991:881.
9Clark AJ, Shmnedzai SH. Allan LG, et al. Efficacy and safety oftransdermal fentanyl and sustained-released oral morphine in patients with cancer and chronic noncancer pain [J]. Current Med Res Opin, 2004, 20 (9):1419-1428.
10Tawfik MO, Bryuzgin V, Kourteva G. Us of tmnsdermal fentanyl without prior opioid stabilization in patients with cancer pain [J]. Curr Med Res Opin, 2004, 20(3):259-267.
6[1]Payne R,Chandler S,Einhaus M.Guidelines for the clinical use of transdermal fentanyl.Anticancer Drugs,1995,6:50～53.
7[2]Payne R,Mathias SD,Pasta DJ,et al.Quality of life and cancer pain:satisfaction and side effects with transdermal fentanyl versus oral morphine.J Clin Oncol 1998,16:1588～1593.
8[4]Donner B,Zenz M,Tryba M,et al.Fentanyl-TTS for postoperative pain therapy.A new alternative? Anaesthesist,1993,42:309～315.
9[5]Paoloni R,Talbot-Stern JP.Low incidence of nausea and vomiting with intravenous opiate analgesia in the ED.Am J Emerg Med,2002,20:604～608.
10[6]Higgs CM,Vella Brincat J.Withdrawal with transdermal fentanyl.J Pain Symptom Manage.1995,10:4～5.
